Lifecore Biomedical Inc (LFCR) Stock Price, Quote & News

Latest News on LFCR

Jan 17, 2025, 5:24 PM EST - 8 hours ago

Lifecore Biomedical Announces Special Stockholder Meeting

Jan 14, 2025, 10:00 AM EST - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Connect

Jan 13, 2025, 10:00 AM EST - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out

Jan 12, 2025, 10:00 AM EST - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation

Jan 10, 2025, 10:00 AM EST - 7 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 9, 2025, 10:00 AM EST - 8 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Connect

Jan 7, 2025, 10:00 AM EST - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation

Jan 7, 2025, 9:00 AM EST - 10 days ago

Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Jan 6, 2025, 4:05 PM EST - 11 days ago

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 10:00 AM EST - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation

Jan 3, 2025, 10:00 AM EST - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out

Jan 2, 2025, 6:19 PM EST - 15 days ago

Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript

Jan 2, 2025, 4:05 PM EST - 15 days ago

Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

Jan 2, 2025, 10:00 AM EST - 15 days ago

Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 2, 2025, 10:00 AM EST - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect

Dec 31, 2024, 10:00 AM EST - 17 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation

Dec 30, 2024, 3:30 PM EST - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

Dec 19, 2024, 4:05 PM EST - 4 weeks ago

Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025

Dec 19, 2024, 7:00 AM EST - 4 weeks ago

Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

Dec 1, 2024, 10:40 AM EST - 6 weeks ago

Lifecore Biomedical: An Interesting CDMO Pure Play

Nov 26, 2024, 4:05 PM EST - 7 weeks ago

Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

Nov 21, 2024, 4:17 PM EST - 2 months ago

Lifecore Biomedical Hosts Virtual Investor Day

Nov 12, 2024, 4:05 PM EST - 2 months ago

Lifecore Biomedical to Present at Stephens Annual Investment Conference

Nov 7, 2024, 7:00 AM EST - 2 months ago

Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024

Nov 4, 2024, 7:00 AM EST - 2 months ago

Lifecore Biomedical Appoints Thomas Guldager as Vice President, Operations

Oct 11, 2024, 9:44 AM EDT - 3 months ago

Johnson Fistel LLP Investigates Lifecore Biomedical, Inc's Directors and Officers for Breach of Fiduciary Duties and Encourages Long Term Shareholders to Reach Out for Their Options

Oct 4, 2024, 10:59 AM EDT - 3 months ago

Lifecore Biomedical, Inc. (LFCR) Q1 2025 Earnings Call Transcript

Oct 4, 2024, 7:30 AM EDT - 3 months ago

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Oct 4, 2024, 7:20 AM EDT - 3 months ago

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Oct 3, 2024, 4:05 PM EDT - 3 months ago

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Oct 1, 2024, 7:00 AM EDT - 3 months ago

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

Sep 28, 2024, 11:00 AM EDT - 3 months ago

The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc

Sep 27, 2024, 11:00 AM EDT - 4 months ago

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Invited To Reach Out To The Schall Law Firm

Sep 27, 2024, 10:32 AM EDT - 4 months ago

FINAL DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Sep 26, 2024, 11:00 AM EDT - 4 months ago

The Schall Law Firm Urges Investors To Join A Securities Fraud Case Against Lifecore Biomedical Inc

Sep 25, 2024, 4:05 PM EDT - 4 months ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Sep 25, 2024, 11:00 AM EDT - 4 months ago

Lifecore Biomedical, Inc. Is Being Sued For Violating Securities Laws And Shareholders Are Invited To Reach Out To The Schall Law Firm

Sep 24, 2024, 11:00 AM EDT - 4 months ago

The Schall Law Firm Urges Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc

Sep 23, 2024, 1:26 PM EDT - 4 months ago

Lifecore Biomedical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 27, 2024 Deadline to file Lead Plaintiff Motion

Sep 23, 2024, 11:00 AM EDT - 4 months ago

Lifecore Biomedical, Inc. Is Being Sued For Possible Securities Law Violations And Shareholders Are Invited To Contact The Schall Law Firm

Sep 23, 2024, 10:40 AM EDT - 4 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

$Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm$

Sep 21, 2024, 11:00 AM EDT - 4 months ago

Lifecore Biomedical, Inc. Is Being Sued For Securities Related Infractions And Impacted Stockholders Are Invited To Contact The Schall Law Firm

Sep 20, 2024, 11:00 AM EDT - 4 months ago

The Schall Law Firm Encourages Investors To Take Part In A Case Against Lifecore Biomedical Inc For Securities Fraud

Sep 19, 2024, 11:00 AM EDT - 4 months ago

Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm

Sep 19, 2024, 10:41 AM EDT - 4 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Sep 19, 2024, 7:00 AM EDT - 4 months ago

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational

Sep 18, 2024, 11:00 AM EDT - 4 months ago

Market Cap	238.44M
Revenue (ttm)	128.26M
Net Income (ttm)	12.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	9.36%
Debt to Equity Ratio	2.39

Volume	82,500
Avg Vol	277,276
Day's Range	N/A - N/A
Shares Out	37.03M
Stochastic %K	35%
Beta	0.98
Analysts	Sell
Price Target	$8.00